Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac myosin inhibitors (CMIs) are being developed to help patients with hypertrophic obstructive cardiomyopathy (HOCM), a disease in which the heart muscle becomes thickened, leading to reduced blood flow out of the heart. In a new analysis led by researchers from Mass General Brigham, investigators probed multiple exercise response patterns before and after exposure to the CMI aficamten in the SEQUIOA-HCM trial.
Medical Xpress – latest medical and health news stories
